Atlas Trials

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

Clinical trial NCT05623774 · COMPLETED

Trial details

NCT number
NCT05623774
Sponsor
Inhibikase Therapeutics
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
CML
Start date
2022-12-16
Primary completion
2024-06-30
Enrollment
64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.